257 related articles for article (PubMed ID: 34782742)
1. A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization.
Dilworth D; Hanley RP; Ferreira de Freitas R; Allali-Hassani A; Zhou M; Mehta N; Marunde MR; Ackloo S; Carvalho Machado RA; Khalili Yazdi A; Owens DDG; Vu V; Nie DY; Alqazzaz M; Marcon E; Li F; Chau I; Bolotokova A; Qin S; Lei M; Liu Y; Szewczyk MM; Dong A; Kazemzadeh S; Abramyan T; Popova IK; Hall NW; Meiners MJ; Cheek MA; Gibson E; Kireev D; Greenblatt JF; Keogh MC; Min J; Brown PJ; Vedadi M; Arrowsmith CH; Barsyte-Lovejoy D; James LI; Schapira M
Nat Chem Biol; 2022 Jan; 18(1):56-63. PubMed ID: 34782742
[TBL] [Abstract][Full Text] [Related]
2. A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin.
Sankaran SM; Wilkinson AW; Elias JE; Gozani O
J Biol Chem; 2016 Apr; 291(16):8465-74. PubMed ID: 26912663
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors.
Li N; Yang H; Liu K; Zhou L; Huang Y; Cao D; Li Y; Sun Y; Yu A; Du Z; Yu F; Zhang Y; Wang B; Geng M; Li J; Xiong B; Xu S; Huang X; Liu T
J Med Chem; 2022 Jul; 65(13):9459-9477. PubMed ID: 35704853
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2.
Ferreira de Freitas R; Liu Y; Szewczyk MM; Mehta N; Li F; McLeod D; Zepeda-Velázquez C; Dilworth D; Hanley RP; Gibson E; Brown PJ; Al-Awar R; James LI; Arrowsmith CH; Barsyte-Lovejoy D; Min J; Vedadi M; Schapira M; Allali-Hassani A
J Med Chem; 2021 Feb; 64(3):1584-1592. PubMed ID: 33522809
[TBL] [Abstract][Full Text] [Related]
5. Histone and DNA binding ability studies of the NSD subfamily of PWWP domains.
Zhang M; Yang Y; Zhou M; Dong A; Yan X; Loppnau P; Min J; Liu Y
Biochem Biophys Res Commun; 2021 Sep; 569():199-206. PubMed ID: 34271259
[TBL] [Abstract][Full Text] [Related]
6. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
[TBL] [Abstract][Full Text] [Related]
7. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.
Li W; Tian W; Yuan G; Deng P; Sengupta D; Cheng Z; Cao Y; Ren J; Qin Y; Zhou Y; Jia Y; Gozani O; Patel DJ; Wang Z
Nature; 2021 Feb; 590(7846):498-503. PubMed ID: 33361816
[TBL] [Abstract][Full Text] [Related]
9. ISWI chromatin remodeling complexes recruit NSD2 and H3K36me2 in pericentromeric heterochromatin.
Goto N; Suke K; Yonezawa N; Nishihara H; Handa T; Sato Y; Kujirai T; Kurumizaka H; Yamagata K; Kimura H
J Cell Biol; 2024 Aug; 223(8):. PubMed ID: 38709169
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in nuclear receptor-binding SET domain 2 (NSD2) inhibitors: An update and perspectives.
Zhang L; Zha X
Eur J Med Chem; 2023 Mar; 250():115232. PubMed ID: 36863225
[TBL] [Abstract][Full Text] [Related]
11. Discovery of NSD2-Degraders from Novel and Selective DEL Hits.
LegaardAndersson J; Christensen J; Kleine-Kohlbrecher D; Vacher Comet I; Fullerton Støier J; Antoku Y; Poljak V; Moretti L; Dolberg J; Jacso T; Jensby Nielsen S; Nørregaard-Madsen M; Franch T; Helin K; Cloos PAC
Chembiochem; 2023 Dec; 24(24):e202300515. PubMed ID: 37807669
[TBL] [Abstract][Full Text] [Related]
12. Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36.
Poulin MB; Schneck JL; Matico RE; McDevitt PJ; Huddleston MJ; Hou W; Johnson NW; Thrall SH; Meek TD; Schramm VL
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1197-201. PubMed ID: 26787850
[TBL] [Abstract][Full Text] [Related]
13. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
[TBL] [Abstract][Full Text] [Related]
14. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
[TBL] [Abstract][Full Text] [Related]
15. Nucleosome Binding Alters the Substrate Bonding Environment of Histone H3 Lysine 36 Methyltransferase NSD2.
Poulin MB; Schneck JL; Matico RE; Hou W; McDevitt PJ; Holbert M; Schramm VL
J Am Chem Soc; 2016 Jun; 138(21):6699-702. PubMed ID: 27183271
[TBL] [Abstract][Full Text] [Related]
16. Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.
Popovic R; Martinez-Garcia E; Giannopoulou EG; Zhang Q; Zhang Q; Ezponda T; Shah MY; Zheng Y; Will CM; Small EC; Hua Y; Bulic M; Jiang Y; Carrara M; Calogero RA; Kath WL; Kelleher NL; Wang JP; Elemento O; Licht JD
PLoS Genet; 2014 Sep; 10(9):e1004566. PubMed ID: 25188243
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of the regulation of the normal and oncogenic methylation of nucleosomal histone H3 Lys36 by NSD2.
Sato K; Kumar A; Hamada K; Okada C; Oguni A; Machiyama A; Sakuraba S; Nishizawa T; Nureki O; Kono H; Ogata K; Sengoku T
Nat Commun; 2021 Nov; 12(1):6605. PubMed ID: 34782608
[TBL] [Abstract][Full Text] [Related]
18. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
[TBL] [Abstract][Full Text] [Related]
19. Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma.
Jiang H; Wang Y; Wang J; Wang Y; Wang S; He E; Guo J; Xie Y; Wang J; Li X; Peng Z; Wang M; Hou J; Liu Z
Clin Transl Med; 2022 Apr; 12(4):e744. PubMed ID: 35389552
[TBL] [Abstract][Full Text] [Related]
20. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.
Huang Z; Wu H; Chuai S; Xu F; Yan F; Englund N; Wang Z; Zhang H; Fang M; Wang Y; Gu J; Zhang M; Yang T; Zhao K; Yu Y; Dai J; Yi W; Zhou S; Li Q; Wu J; Liu J; Wu X; Chan H; Lu C; Atadja P; Li E; Wang Y; Hu M
Cancer Res; 2013 Oct; 73(20):6277-88. PubMed ID: 23980095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]